Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 5 | 2022 | 208 | 1.380 |
Why?
|
| Ovarian Neoplasms | 5 | 2022 | 771 | 1.120 |
Why?
|
| Genital Neoplasms, Female | 2 | 2020 | 108 | 0.760 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2019 | 160 | 0.730 |
Why?
|
| Salpingo-oophorectomy | 1 | 2020 | 3 | 0.700 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 86 | 0.650 |
Why?
|
| Tubulin Modulators | 1 | 2018 | 23 | 0.620 |
Why?
|
| Drug Carriers | 1 | 2019 | 82 | 0.620 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2019 | 665 | 0.610 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2018 | 75 | 0.590 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 557 | 0.560 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 160 | 0.480 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 250 | 0.480 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1065 | 0.470 |
Why?
|
| Natural Childbirth | 1 | 2014 | 1 | 0.460 |
Why?
|
| Midwifery | 1 | 2014 | 2 | 0.460 |
Why?
|
| Home Childbirth | 1 | 2014 | 2 | 0.460 |
Why?
|
| Pregnant Women | 1 | 2014 | 41 | 0.440 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 120 | 0.430 |
Why?
|
| Obstetrics | 1 | 2014 | 122 | 0.390 |
Why?
|
| Dementia | 2 | 2023 | 203 | 0.370 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 198 | 0.310 |
Why?
|
| Mice, SCID | 2 | 2019 | 259 | 0.300 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 486 | 0.280 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2018 | 51 | 0.280 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 2588 | 0.230 |
Why?
|
| Metformin | 2 | 2016 | 124 | 0.230 |
Why?
|
| Female | 13 | 2023 | 46656 | 0.210 |
Why?
|
| Adnexal Diseases | 1 | 2022 | 16 | 0.200 |
Why?
|
| Antipsychotic Agents | 1 | 2023 | 131 | 0.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 47 | 0.190 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 155 | 0.190 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 97 | 0.170 |
Why?
|
| Menopause, Premature | 1 | 2019 | 3 | 0.160 |
Why?
|
| Cell Growth Processes | 1 | 2018 | 85 | 0.150 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 88 | 0.150 |
Why?
|
| Humans | 14 | 2023 | 90071 | 0.150 |
Why?
|
| RNA Interference | 1 | 2019 | 376 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2019 | 165 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 568 | 0.140 |
Why?
|
| Paclitaxel | 1 | 2018 | 474 | 0.130 |
Why?
|
| Cell Cycle | 1 | 2018 | 508 | 0.130 |
Why?
|
| Hysterectomy | 1 | 2017 | 156 | 0.130 |
Why?
|
| Hypoglycemic Agents | 2 | 2016 | 352 | 0.130 |
Why?
|
| Palliative Care | 1 | 2018 | 264 | 0.130 |
Why?
|
| Mice | 3 | 2019 | 11869 | 0.130 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 21 | 0.130 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 61 | 0.120 |
Why?
|
| Cell Movement | 1 | 2019 | 787 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2019 | 776 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2018 | 384 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2015 | 172 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 654 | 0.110 |
Why?
|
| Middle Aged | 4 | 2023 | 26195 | 0.110 |
Why?
|
| Pandemics | 3 | 2023 | 778 | 0.100 |
Why?
|
| Apoptosis | 1 | 2018 | 1718 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 320 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 2361 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2891 | 0.090 |
Why?
|
| Animals | 3 | 2019 | 27553 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1284 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1350 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2019 | 9259 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 3021 | 0.070 |
Why?
|
| Young Adult | 1 | 2020 | 6424 | 0.070 |
Why?
|
| Adolescent | 1 | 2020 | 9363 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2323 | 0.070 |
Why?
|
| Pregnancy | 1 | 2014 | 3044 | 0.070 |
Why?
|
| Adult | 3 | 2020 | 26855 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1731 | 0.060 |
Why?
|
| United Kingdom | 1 | 2023 | 165 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 2000 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 58 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 151 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2023 | 111 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2022 | 720 | 0.040 |
Why?
|
| Aged | 3 | 2023 | 19282 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 49 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2019 | 82 | 0.040 |
Why?
|
| Hope | 1 | 2018 | 5 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1081 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 1604 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 60 | 0.040 |
Why?
|
| Trust | 1 | 2018 | 97 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2018 | 186 | 0.030 |
Why?
|
| Phenformin | 1 | 2015 | 5 | 0.030 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2015 | 12 | 0.030 |
Why?
|
| Ascites | 1 | 2015 | 56 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2015 | 93 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 126 | 0.030 |
Why?
|
| Glycolysis | 1 | 2015 | 135 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 198 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1684 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 983 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 6786 | 0.030 |
Why?
|
| Glucose | 1 | 2015 | 628 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 1901 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2658 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 5364 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3689 | 0.020 |
Why?
|
| Male | 2 | 2023 | 42741 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3257 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 3800 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 2328 | 0.010 |
Why?
|